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Cell Stem Cell
Editors’ NotesMore than Meets the ‘‘i’’
The pool of growth and transcription factors that mediate pluripotent reprogramming is still expanding, and new evidence
suggests that established iPSC factors and signals may play unexpected roles in this process. Smith and colleagues manip-
ulate STAT3 activation to show that signals downstream of the recognized pluripotency maintenance factor LIF also play anactive role during iPSC generation. Dalton and coauthors manipulate Myc
expression, one of the original Yamanaka reprogramming factors, and
demonstrate that N-Myc or c-Myc are necessary to repress differentiation
of pluripotent cells, in addition to their accepted role as cell cycle mediators.Modeling Cancer
The two most common approaches for using animal models to assess the
cellular properties of human tumors are genetic modifications to mimic
human tumor mutations or transplantation of human cells into immunodefi-
cient hosts. Smalley et al. have taken the former approach, and find thatBrca1 deletion, as seen in many human basal-like breast cancers, only mimics human tumor phenotypes when targeted to
luminal progenitors, suggesting that the human cell-of-origin may not be the basal stem cell, as previously thought. Matsui,
Neel, and colleagues, on the other hand, examine xenograft transplantation assays, and also buck current trends by showing
that human tumor initiating cells can be rare even under optimized, highly immune deficient conditions, and their frequency
may vary according to the stage and tissue origin of a given tumor.Fabricating Function
Animal models are also important tools for early functional experiments after derivation of differentiated cell types. Wichterle
and colleagues use a mouse-chick chimera system to show that they can derive specific motor neuron subtypes from ESCs
by using defined growth conditions. The resulting subpopulations migrated to spinal cord regions that matched their pheno-
type in culture. Although these studies are still at an early stage, this type of analysis is an essential forerunner for cell-based
clinical interventions. In their Forum article, Cote´ and coauthors from the United States Food and Drug Administration (FDA)
describe how theOrphanDrug Act relates to, and can support, development of stem cell-derived therapeutic agents andwhat
steps have been taken thus far to apply stem cell research to the treatment of rare diseases.Epigenetics Set the Stage
The reprogramming field has drawn attention to the importance, and malleability, of epigenetic control of cell fate. Plath and
coauthors examine the process of human X chromosome inactivation during fibroblast reprogramming and find that althoughsome epigenetic repatterning does occur, female somatic cell-derived iPSCs do not
reactivate their inactive X. Two Review articles in this issue also explore how cell fates
are regulated at the epigenetic level, specifically by polycomb group (PcG) proteins.
Boyer and colleagues consider PcG participation in pluripotent cell lineage commit-
ment decisions, whereas Sauvageau and Sauvageau focus on tissue-specific stem
cells and cancer.Niche Division
Niche-mediated regulation of stem cell function involves extrinsic inputs that
modulate cell fate. In this vein, two studies in this issue highlight how environmental
conditions communicate metabolic instructions to resident stem cells, in this case,
to bone marrow HSCs. Sadek and colleagues demonstrate that the low oxygen
concentrations present in marrow prompt HSCs to utilize glycolysis rather than
oxidative phosphorylation and that Meis1 activates Hif-1a to regulate this process.Suda and coauthors also examine the impact of Hif-1a on HSC function and show that, in the absence of this factor,
HSC quiescence is lost and the pool of LT-HSCs is exhausted under stress conditions. Stem cell division in response to envi-
ronmental cues is also a theme in the article from Farin˜as and colleagues. These authors show that the symmetry and
outcome of NSC divisions in the subependymal zone depend on input mediated by the EGFR, via a modulating kinase,
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